Entries by Evgeniy Makarevich

THE RUSSIAN COMPANY TAKEDA ANNOUNCED REGISTRATION IN RUSSIA OF A NEW READINGS OF ADCETRIS® PREPARATION (BRENTUKSIMAB VEDOTIN)

Takeda Russia announced the launch of two new indications of Adsetris® on the Russian market: 1) the treatment of previously untreated patients with classical CD30 + Hodgkin’s lymphoma stage IV in combination with doxorubicin, vinblastine and dacarbazine; 2) the treatment of patients with CD30 + T-cell lymphoma of the skin after at least one line […]

The second stage of clinical trials of a drug for the treatment of systemic lupus erythematosus has begun in China

Chinese scientists have begun the second phase of clinical trials of the drug for the treatment of an autoimmune disease – systemic lupus erythematous. The new patent-protected drug SM934, which is a water-soluble artemisinin derivative, was developed by researchers at the Shanghai Institute of Pharmacology at the Academy of Sciences of China ANC. The first stage of […]

Sanofi gets rights to Tamiflu in the US market

The French group Sanofi has signed an agreement with Roche on the transfer of rights to the antiviral drug Tamiflu (oseltamivir) in the United States. Sanofi will receive exclusive rights to Tamiflu over-the-counter in the United States.  This drug is intended for the prevention and treatment of influenza. Alan Main, executive vice president of consumer […]

Trastuzumab and bevacizumab biosimilars enter the US market

For a long time, Roche’s three drugs, Rituxan, Herceptin and Avastin, dominated the global market. However, on July 18, their competitors appeared – Amgen and Allergan introduced the biosimilars of Herceptin preparations for the treatment of HER2-positive breast cancer and Avastin for the treatment of colorectal cancer to the USA, which threatened the total sales […]

FDA Approved Bayer Gadavist Contrast Agent Contrast Agent

Bayer Gadavist (gadobutrol) is the first and only contrast agent for use in cardiac magnetic resonance imaging (CMRT) in adult patients with diagnosed or suspected coronary heart disease (CHD) and has been approved by the FDA. This decision is based on the data of two prospective multicenter open phase non-randomized blind clinical trials of the […]

R-Pharm will bring technology for the early diagnosis of lung cancer to the Russian market

The R-Pharm group of companies, together with the British developer Oncimmune Holdings, have signed an exclusive agreement to introduce the EarlyCDT Lung product for early detection of lung cancer to the Russian and Eurasian Customs Union countries. The development of Oncimmune is a specific blood test technology that facilitates the early detection of lung cancer […]

FDA approved Xembify® for the treatment of primary immunodeficiency

Grifols, the leading global manufacturer of plasma-based drugs, announced its approval of its new drug, Xembify®, by the FDA (Food and Drug Administration). Chembify® is a 20% subcutaneous immunoglobulin used to treat primary immunodeficiency. Now Grifols is one of the leaders in the market for the production and sale of the immunoglobulin – the company’s […]

GEROPHARM registered the first Russian insulin bioanalogue

GEROPHARM received a registration certificate for two-phase insulin lispro under the trade name RinLiz®. These are the first Russian bioanalogues of ultrashort and medium duration insulin in the GEROPHARM portfolio. The company plans to produce them on a full cycle basis – from substance to finished dosage form. Now on the Russian market insulin lispro […]